- Two-year survival has increased to 93% for newly-diagnosed patients. The survival rate for people without myeloma is only three percent higher,
- Velcade has produced a high complete-response (CR) rate, and
- Further improvements are made by using Revlimid and Velcade in sequence or in combination.
Stick around, it's getting better and better!